{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Liminatus Pharma, Inc."},"Symbol":{"label":"Symbol","value":"LIMN"},"Address":{"label":"Address","value":"3524 SILVERSIDE ROAD SUITE 35B, WILMINGTON, Delaware, 19810, United States"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":null},"Sector":{"label":"Sector","value":null},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Liminatus Pharma, Inc. is pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company's candidate IBA101, is a humanized anti CD47 monoclonal antibody. The next generation CD47 checkpoint inhibitor's initial indication is expected to be patients with advanced solid cancers including non-small cell lung cancer. The Company's vision is to develop a broad array of transformative therapies for cancer patients as a leading global biopharmaceutical company."},"CompanyUrl":{"label":"Company Url","value":null}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}